NEWS 
& MEDIA

NEWS
RELEASES

Back View printer friendly version
Takeda to Hold Oncology Focused Investor Call on June 8

Osaka, JAPAN & Cambridge, MASS., May 28, 2021 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will hold an oncology focused Investor Call on Tuesday, June 8, 2021 at 6:30 p.m. ET / Wednesday, June 9 at 7:30 a.m. JST. Teresa Bitetti, president, Global Oncology Business Unit, and Chris Arendt, head, Oncology Therapeutic Area Unit, Takeda, will provide an overview of the oncology portfolio and pipeline, including updates from the 57th American Society of Clinical Oncology (ASCO) Annual Meeting. The call will be followed by a Q&A session.

Please contact TakedaRandDEvents@fticonsulting.com for further details. Presentation slides and an archived replay of the webcast will be available at https://www.takeda.com/investors/reports/ir-events/.

Media Contacts:

Japanese Media
Ryoko Matsumoto
ryoko.matsumoto@takeda.com
+81 (0) 3-3278-3414

Media Outside Japan
Lauren Padovan
lauren.padovan@takeda.com
+1 (617) 444-1419

Takeda’s Commitment to Oncology

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.